This content is machine translated Direct oral anticoagulants DOAKs in renal insufficiency – GFR tipping the scales Any anticoagulation is a balancing act between thromboembolism and bleeding risk. This is particularly true in the case of chronic kidney dysfunction (CKD). In mild to moderate renal disease, all…
View Post 6 min This content is machine translated Advanced renal cell carcinoma New points of attack under the microscope Even in the era of VEGF and checkpoint inhibitors, the prognosis for advanced renal cell carcinoma remains poor. The use of targeted therapies and immunotherapeutic approaches is difficult due to…
View Post 1 min This content is machine translated Continuing education series on type 2 diabetes (2021) Dia-Month Club Module 5: Kidney On October 26, the fifth module of the Dia-Month Club was held on the topic of kidneys. Our expert, PD Dr. Michael Mayr (University Hospital Basel), explained the practical guardrails… CME-Test
View Post 4 min This content is machine translated GLP-1 receptor agonists (GLP-1-RA) Type 2 diabetics benefit from dulaglutide in several ways The ADA/EASD guidelines recommend individualized therapy choices for type 2 diabetics. GLP-1 receptor agonists not only improve glycemic control, but also support weight loss, reduce the risk of cardiovascular disease,…
View Post 7 min This content is machine translated Lupus nephritis Special case kidney For a long time, the treatment of lupus was characterized by stagnation. However, after 20 years of frustration, there is finally movement to develop new therapeutic options. Studies have produced promising results…
View Post 5 min This content is machine translated Diabetic nephropathy SGLT-2 inhibitor protects heart and kidney also in the real-world setting Type 2 diabetes mellitus (T2DM) significantly increases the risk of cardiovascular and renal diseases [1, 2]. However, SGLT-2 inhibitors not only lower blood glucose levels but also have cardio- and…
View Post 11 min This content is machine translated Role of incretin-based therapy GLP-1-RA and DPP-4 inhibitors in the management of type 2 diabetes. Insulin secretion by pancreatic beta cells is primarily influenced by glucose levels in the portal vein. In addition, secretion is also modulated by the so-called incretins. After food intake, they…
View Post 17 min This content is machine translated Systemic vasculitides Therapy in the adult patient Systemic vasculitides are inflammatory syndromes of the blood vessels, which can cause a very broad spectrum of symptoms depending on the affected vessel caliber and localization. The most common primary…
View Post 10 min This content is machine translated Rarer tumor entities Current therapeutic options in metastatic renal cell carcinoma. Renal cell carcinoma is one of the rather rare tumor entities. Therefore, treatment options were very limited for years and therapy was difficult. Meanwhile, tyrosine kinase inhibitors have expanded the…
View Post 3 min This content is machine translated GLP-1 receptor agonists in type 2 diabetes Nephroprotection with semaglutide and liraglutide – direct or indirect effects? In a post-hoc analysis of large randomized placebo-controlled trials, HbA1c and body weight and blood pressure were examined as mediator variables regarding the renal protective effects of the GLP-1 receptor…
View Post 4 min This content is machine translated Diabetic nephropathy SGLT-2 inhibitor slows decline in glomerular filtration rate For the first time, a targeted therapy for diabetic kidney disease is available. In the CREDENCE study, canagliflozin resulted in a clinically relevant and statistically significant risk reduction for renal…
